title: Murine syngeneic graft-versus-host disease is responsive to broad-spectrum antibiotic therapy.
abstract: Murine syngeneic graft-versus-host disease (SGVHD) initiates colon and liver inflammation following lethal irradiation, reconstitution with syngeneic bone marrow transplantation, and therapy with the immunosuppressive agent cyclosporine A. Previous studies have demonstrated that the inducible disease is mediated by CD4(+) T cells with increased reactivity of peripheral and liver-associated lymphocytes against intestinal microbial Ags. In the current report, studies were performed to analyze the specificity of the CD4(+) T cell response of T cells isolated from diseased animals and to determine the in vivo role of the microbiota to the development of SGVHD. Increased major histocompatibility Ag (MHC) class II-restricted responsiveness of SGVHD CD4(+) T cells against microbial Ags isolated from the ceca of normal animals was observed. The enhanced proliferative response was observed in the CD62L(-) memory population of CD4(+) T cells. To determine the role of the bacterial microbiota in the development of murine SGVHD, control and CsA-treated bone marrow transplantation animals were treated with broad-spectrum antibiotics (metronidazole, ciprofloxacin) after transplantation. Cyclosporine A-treated animals that were given antibiotic therapy failed to develop clinical symptoms and pathological lesions in the target tissues characteristic of SGVHD. Furthermore, the reduction in intestinal bacteria resulted in the elimination of the enhanced antimicrobial CD4(+) T cell response and significantly reduced levels of the inflammatory cytokines, IFN-γ, IL-17, and TNF-α. The elimination of the disease-associated inflammatory immune responses and pathology by treatment with broad-spectrum antibiotics definitively links the role of the microbiota and microbial-specific immunity to the development of murine SGVHD.
authors.affiliation: Department of Microbiology, Immunology, and Molecular Genetics, University of Kentucky Medical Center, University of Kentucky, Lexington, KY 40536, USA.
authors.forename: J Anthony
authors.initials: JA
authors.lastname: Brandon
authors.forename: C Darrell
authors.initials: CD
authors.lastname: Jennings
authors.forename: Alan M
authors.initials: AM
authors.lastname: Kaplan
authors.forename: J Scott
authors.initials: JS
authors.lastname: Bryson
mesh_terms: D000818:Animals; D000900:Anti-Bacterial Agents / Q000145:classification / Q000627:therapeutic use*; D016026:Bone Marrow Transplantation / Q000276:immunology / Q000473:pathology; D015496:CD4-Positive T-Lymphocytes / Q000276:immunology / Q000382:microbiology / Q000473:pathology; D002460:Cell Line; D049109:Cell Proliferation; D002939:Ciprofloxacin / Q000627:therapeutic use; D005260:Female; D006086:Graft vs Host Disease / Q000188:drug therapy* / Q000276:immunology* / Q000473:pathology; D000949:Histocompatibility Antigens Class II / Q000276:immunology; D007249:Inflammation / Q000188:drug therapy / Q000276:immunology / Q000473:pathology; D007413:Intestinal Mucosa / Q000276:immunology / Q000382:microbiology / Q000473:pathology; D008795:Metronidazole / Q000627:therapeutic use; D051379:Mice; D008809:Mice, Inbred C3H
chemical_list: D000900:Anti-Bacterial Agents; D000949:Histocompatibility Antigens Class II; D008795:Metronidazole; D002939:Ciprofloxacin